EA202092558A1 - КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ - Google Patents

КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ

Info

Publication number
EA202092558A1
EA202092558A1 EA202092558A EA202092558A EA202092558A1 EA 202092558 A1 EA202092558 A1 EA 202092558A1 EA 202092558 A EA202092558 A EA 202092558A EA 202092558 A EA202092558 A EA 202092558A EA 202092558 A1 EA202092558 A1 EA 202092558A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
met
production
crystalline form
salt form
Prior art date
Application number
EA202092558A
Other languages
English (en)
Other versions
EA039713B1 (ru
Inventor
Сюнбинь Сюй
Ган Ли
Тин Яо
Кунь ВАН
Лихун ХУ
Чарлз З. Дин
Original Assignee
Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуцзянь Косантер Фармасьютикал Ко., Лтд. filed Critical Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Publication of EA202092558A1 publication Critical patent/EA202092558A1/ru
Publication of EA039713B1 publication Critical patent/EA039713B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрыты кристаллическая форма ингибитора c-MET, его солевая форма и способ их получения. В частности, включено соединение, представленное формулой (I), и его солевая форма и кристаллическая форма, а также включено применение кристаллической формы и солевой формы для получения лекарственных препаратов, предназначенных для лечения видов рака.
EA202092558A 2018-04-26 2019-04-26 Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения EA039713B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810387693 2018-04-26
PCT/CN2019/084515 WO2019206268A1 (zh) 2018-04-26 2019-04-26 一种c-MET抑制剂的晶型及其盐型和制备方法

Publications (2)

Publication Number Publication Date
EA202092558A1 true EA202092558A1 (ru) 2021-02-24
EA039713B1 EA039713B1 (ru) 2022-03-03

Family

ID=68294814

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092558A EA039713B1 (ru) 2018-04-26 2019-04-26 Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения

Country Status (12)

Country Link
US (1) US11465986B2 (ru)
EP (1) EP3786155B1 (ru)
JP (1) JP7118349B2 (ru)
KR (1) KR102374933B1 (ru)
CN (1) CN112004801B (ru)
AU (1) AU2019260240B2 (ru)
CA (1) CA3098336C (ru)
EA (1) EA039713B1 (ru)
ES (1) ES2962679T3 (ru)
TW (1) TWI768205B (ru)
WO (1) WO2019206268A1 (ru)
ZA (1) ZA202007037B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943488T3 (es) * 2018-08-23 2023-06-13 Fujian Akeylink Biotechnology Co Ltd Forma cristalina de compuesto tri-ciclo y aplicación del mismo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558272C (en) 2004-03-05 2011-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2373640B1 (en) 2009-01-08 2014-07-30 Merck Patent GmbH Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
EP2768826A1 (de) * 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
HUE051734T2 (hu) 2016-10-27 2021-03-29 Fujian Cosunter Pharmaceutical Co Ltd Piridon-vegyület, mint C-Met inhibitor

Also Published As

Publication number Publication date
JP2021522265A (ja) 2021-08-30
EP3786155A4 (en) 2021-05-19
AU2019260240A1 (en) 2020-12-17
AU2019260240B2 (en) 2023-05-11
JP7118349B2 (ja) 2022-08-16
EA039713B1 (ru) 2022-03-03
EP3786155B1 (en) 2023-08-16
KR102374933B1 (ko) 2022-03-15
CA3098336C (en) 2024-03-19
US11465986B2 (en) 2022-10-11
US20210238163A1 (en) 2021-08-05
KR20210005142A (ko) 2021-01-13
EP3786155A1 (en) 2021-03-03
TWI768205B (zh) 2022-06-21
ES2962679T3 (es) 2024-03-20
TW201945359A (zh) 2019-12-01
CN112004801B (zh) 2023-09-08
WO2019206268A1 (zh) 2019-10-31
ZA202007037B (en) 2021-10-27
CN112004801A (zh) 2020-11-27
CA3098336A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201690094A1 (ru) Ингибиторы syk
EA201891553A1 (ru) Ингибиторы syk
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201690752A1 (ru) Ингибиторы g12c kras
EA201690204A1 (ru) Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201990833A1 (ru) Соединение пиридина
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций